Akoya Biosciences, Inc. Stock Price, News & Analysis

Akoya Biosciences (Nasdaq: AKYA) reported a strong performance for Q3 2022, with revenues of $18.9 million, marking a 40% year-over-year increase. Product revenue rose to $14.4 million, up 32%, driven by a 67% increase in instrument sales with 55 units sold. The installed base has reached 863 instruments. Year-to-date revenue is $53.6 million, up 38%. Gross profit for the quarter was $10.9 million, maintaining a 58% margin. The company has raised its full-year revenue guidance to $73-75 million due to positive growth trends and strong market execution.

Akoya Biosciences (Nasdaq: AKYA) has launched PhenoCode™ Signature Panels for high-throughput spatial biomarker discovery on PhenoImager® platforms. These customizable multiplex panels enable phenotyping of the tumor microenvironment and immune status, streamlining biomarker validation for immuno-oncology applications. This development reflects Akoya's commitment to enhancing predictive tissue-based biomarker solutions, with a focus on accelerating research and clinical trials. Akoya will present their findings at the SITC 37th Annual Meeting in Boston from November 8-12, 2022.

Akoya Biosciences (Nasdaq: AKYA), known as The Spatial Biology Company^®, announced its participation in three investor conferences. These include a fireside chat at the Stephens Annual Investment Conference on November 16, a panel at the Canaccord Genuity Annual MedTech Forum on November 17, and another fireside chat at the Piper-Sandler Annual Healthcare Conference on December 1. Live webcasts will be accessible on Akoya's website.

Akoya Biosciences, Inc. (Nasdaq: AKYA) will announce its Q3 2022 financial results on November 7, 2022, after market close. Following the announcement, management will host a conference call at 5:00 p.m. ET to discuss the results. Interested investors are encouraged to register in advance for the call. Akoya specializes in spatial biology, offering innovative solutions for single-cell imaging and spatial phenotyping, aimed at enhancing understanding of biology and health.

Akoya Biosciences (Nasdaq: AKYA) will participate in four upcoming investor conferences, showcasing its advancements in spatial biology.

The events include:

• H.C. Wainwright 24th Annual Global Investment Conference - September 12 at 11:30 AM ET
• Morgan Stanley 20th Annual Global Healthcare Conference - September 14 at 8:35 AM ET
• Capital One Spatial Biology & Proteomics Summit - September 28 at 10:15 AM and 1:00 PM ET
• Bank of America Healthcare Innovation Forum - September 29 at 11 AM ET

Webcasts of the events will be available on Akoya's website.

Akoya Biosciences (Nasdaq: AKYA) reported a strong Q2 2022 with revenue reaching $17.9 million, a 37% year-over-year growth. Product revenue increased by 33% to $14.2 million, while services and other revenue surged 54% to $3.7 million. The company sold 60 instruments, marking a 94% increase in sales. Akoya also raised its FY 2022 revenue guidance to $71-74 million, supported by $88 million in cash and equivalents. The company expanded its credit facility by $20 million to enhance liquidity.

Akoya Biosciences (Nasdaq: AKYA), The Spatial Biology Company^®, will participate in two investor conferences in August 2022. The first is the UBS Genomics 2.0 and MedTech Innovation Conference, featuring a fireside chat with CEO Brian McKelligon and CBO Niro Ramachandran on August 9^th at 1:00 PM PT. The second event, the Canaccord Growth Conference, includes a panel discussion on spatial omics with CEO McKelligon on August 10^th at 12:00 PM ET. Both sessions will be broadcast live and available for replay.

Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced that it will release its second-quarter financial results on August 8, 2022, after market close. A conference call for investors will take place at 5:00 p.m. ET to discuss these results. Investors can register for the call online and access a webcast on the company’s investor relations website. Akoya specializes in spatial phenotyping, providing advanced single-cell imaging solutions to enhance research in biology and health.

Akoya Biosciences and Acrivon Therapeutics announced a partnership to co-develop the innovative OncoSignature test, designed to identify cancer patients most likely to respond to ACR-368, a targeted oncology agent in Phase 2 trials. ACR-368 aims to treat ovarian, endometrial, and urothelial cancers, with promising results in platinum-resistant ovarian cancer. The OncoSignature will utilize Akoya’s PhenoImager technology for patient selection to enhance treatment outcomes, pending ACR-368's approval.